Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 2/20 | 0.31 |
| ▸ | WEE1 | P30291 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4660475 | 0.72 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3MAPKAPK2PIM1 | |
| SCHEMBL4677595 | 0.72 | ADRB1 (0.41) | — | |
| SCHEMBL4313251 | 0.71 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3MAPKAPK2PIM1 | |
| SCHEMBL15415226 | 0.69 | PIM1 (0.36) | SLC6A2SLC6A4SLC6A3MAP4K1PIM1 | |
| SCHEMBL4313256 | 0.68 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3MAPKAPK2MAP4K1 | |
| SCHEMBL532873 | 0.67 | NPC1 (0.50) | SLC6A2SLC6A4SLC6A3MAPKAPK2 | |
| SCHEMBL4313200 | 0.67 | HTR2C (0.34) | SLC6A2SLC6A4SLC6A3PIM1 | |
| SCHEMBL85663 | 0.66 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3MAPKAPK2MAP4K1 | |
| SCHEMBL3656969 | 0.66 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3MAPKAPK2 | |
| Hydrochloric Acid SCHEMBL2854834 | 0.66 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359371-B2 | Bicyclic substituted pyrimidine compounds | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | claimed |
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2015-08-20 | — | — | US | claimed |
| EP-2886540-A1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-24 | — | — | EP | claimed |
| US-9359371-B2 | Bicyclic substituted pyrimidine compounds | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2015-08-20 | — | — | US | disclosed |
| EP-2886540-A1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232474-A1 | Bicyclic Substituted Pyrimidine Compounds | DPYD, UMPS, TYMP | SLC6A2 500/4885SLC6A4 426/4885SLC6A3 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.